This six-month phase 3 study was seeking to enroll 108 patients with amyotrophic lateral sclerosis (ALS) who had a mutation in the superoxide dismutase type 1 (SOD1) gene. BBK had successfully supported phase 1 enrollment.
Since patients may not have known whether they had the mutation, genetic testing was included as part of the initial screening.
Because of the limited patient population, efforts were needed to ensure that all study participants remained engaged with services that facilitated their participation.
The investigational drug QALSODY (tofersen) has since been approved by the FDA – its approval has been considered a major scientific advancement as the first treatment to target a genetic cause of ALS.
Only about two percent of all ALS patients have a mutation in the SOD1 gene.
Because many ALS patients do not know if they have a mutation in the SOD1 gene, they may not immediately identify with the study opportunity.
Patient burden when traveling to and from study appointments.
Concern among patients about the possibility of being randomized to the placebo group.
Through a detailed prescreening process designed to rank and identify potential participants based on their knowledge of their condition, including ALS diagnosis history, SOD1 testing status, history of familial ALS, and willingness to participate in clinical research, BBK generated over 1,700 highly qualified referrals.
BBK ‘s TCN™ Card reimbursement program ensured patients would be reimbursed immediately anywhere in the world. BBK’s TCN™ Arrive travel program extended to in-country and cross-border travel for patients and their caregivers.
Ambulance Transports
Site: Île-de-France, France
A patient in France required an ambulance to transport them to and from study visits as their condition progressed.
Wheelchair Accessibility
Site: Quebec, Canada
A patient in Quebec required added support as their mobility declined.
Hospital Bed Rental
Site: Florida, United States
Staff at a site in Florida requested assistance from BBK’s concierge specialists to help source a hospital bed that could be rented for one of their patients.
BBK supported the sponsor’s pipeline of related ALS studies with branding and material development. The study logos differentiated each study while maintaining a strong brand consistency across all materials.
Download the PDF version of this case study today:
Case Studies
October 12, 2021
Case Studies
December 13, 2021
Case Studies
February 5, 2022
BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States
Terms & Conditions Privacy Policy
© 2024 BBK Worldwide. BBK Worldwide is a Publicis Health company.
Terms & Conditions Privacy Policy
© 2024 BBK Worldwide. BBK Worldwide is a Publicis Health company.